Navigation Links
Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q2 2013
Date:10/28/2013

London (PRWEB) October 28, 2013

Summary

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q2 2013” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&A) and financing in the pharmaceutical and healthcare market. The report provides detailed information on partnerships, licensing agreements, M&As, equity/debt offerings, private equity and venture financing transactions recorded in the pharmaceutical and healthcare industry in Q2 2013. The report presents detailed comparative data on the number of deals and their value in the last five quarters, categorized into deal types, segments, and geographies. The report also provides information on the top venture capital and advisory firms in the pharmaceutical and healthcare industry.

GlobalData derived the data presented in this report from proprietary in-house deals database and primary and secondary research.

Scope

-Analysis of the market trends for the pharmaceutical industry in the global arena.
-Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
-Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
-Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
-Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
-Analysis of partnership and licensing deals based on clinical stage of development of products.
-Summary of the pharmaceutical deals globally in the last five quarters.
-Information on the top deals happened in the pharmaceutical industry.
-Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
-League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

-Enhance your decision making capability in a more rapid and time sensitive manner.
-Find out the major deal performing segments for investments in your industry.
-Evaluate the types of company divesting and acquiring assets and ways to raise capital in the market.
-Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the oil and gas industry.
-Identify growth segments and opportunities in each region within the industry.
-Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 11
2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q2 2013 15
2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q2 2013 15
2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q2 2013 18
2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q2 2013 19
2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q2 2013 20
2.4.1 Life Technologies Receives Shareholders Approval for Its Acquisition by Thermo Fisher Scientific for US$13.6 Billion 20
2.4.2 Valeant Pharma Completes Acquisition of Bausch & Lomb for US$ 8.7 Billion 22
2.4.3 Actavis Receives French Competition Authority Approval to Acquire Warner Chilcott for US$8.5 Billion 23
2.4.4 Merck Completes Public Offering of Notes for US$6.5 Billion 24
2.4.5 Tenet Healthcare to Acquire Vanguard Health Systems for US$4.3 Billion 25
3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 26
3.1 Pharmaceuticals & Healthcare, Global, M&A, Q2 2013 26
3.1.1 Top M&A Deals in Q2 2013 28
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q2 2012 - Q2 2013 29
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q2 2013 31
3.2.1 Top Initial Public Offerings in Q2 2013 32
3.2.2 Top Secondary Offerings in Q2 2013 32
3.2.3 Top PIPE Deals in Q2 2013 33
3.2.4 Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q2 2012-Q2 2013 33
3.2.5 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q2 2012 - Q2 2013 34
3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q2 2013 36
3.3.1 Top Venture Financing Deals in Q2 2013 37
3.3.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q2 2013 38
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q2 2013 39
3.3.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q2 2012 - Q2 2013 40
3.3.5 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Last Four Quarters 42
3.3.6 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Last One Year 44
3.4 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q2 2013 45
3.4.1 Top Private Equity Deals in Q2 2013 46
3.4.2 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q2 2012 - Q2 2013 47
4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q2 2013 49
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q2 2013 49
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q2 2012 - Q2 2013 51
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2013 53
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q2 2013 54
4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q2 2013 55
4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q2 2013 56
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2012 - Q2 2013 57
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q2 2012 - Q2 2013 59
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q2 2012 - Q2 2013 60
4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2012 - Q2 2013 62
5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q2 2013 64
5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q2 2013 64
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q2 2012 - Q2 2013 66
5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q2 2013 68
5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q2 2013 68
5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q2 2013 69
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q2 2012 - Q2 2013 70
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q2 2012 - Q2 2013 72
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q2 2012 - Q2 2013 74
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q2 2012 - Q2 2013 75
5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q2 2012 - Q2 2013 77
6 Pharmaceuticals & Healthcare, Global, M&A Financial Analysis 79
6.1 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value versus Median Deal Value, Q2 2012 - Q2 2013 79
6.2 Pharmaceuticals& Healthcare, Global Acquisitions, Average Price Earnings of Acquired Companies, Q2 2012 - Q2 2013 81
6.3 Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q2 2012 - Q2 2013 83
6.4 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q2 2012 - Q2 2013 85
6.5 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Market Price Per Share, Q2 2012 - Q2 2013 87
6.6 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Book Value Per Share, Q2 2012 - Q2 2013 89
6.7 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q2 2012 - Q2 2013 90
7 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 92
7.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q2 2013 92
7.1.1 Oncology - Deals of the Quarter 94
7.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q2 2013 96
7.2.1 Central Nervous System - Deals of the Quarter 98
7.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q2 2013 99
7.3.1 Infectious Disease - Deals of the Quarter 101
7.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q2 2013 103
7.4.1 Immunology - Deals of the Quarter 105
7.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q2 2013 106
7.5.1 Metabolic Disorders - Deals of the Quarter 108
7.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q2 2013 110
7.6.1 Cardiovascular - Deals of the Quarter 112
7.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q2 2013 114
7.7.1 Gastrointestinal - Deals of the Quarter 116
7.8 Pharmaceuticals & Healthcare, Global, Ophthalmology Deals, Q2 2013 117
7.8.1 Ophthalmology - Deals of the Quarter 119
7.9 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q2 2013 120
7.9.1 Respiratory - Deals of the Quarter 122
7.10 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q2 2013 124
7.10.1 Dermatology - Deals of the Quarter 126
8 Deal Summary by Geography 127
8.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q2 2013 127
8.1.1 North America - Deals of the Quarter 129
8.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q2 2013 132
8.2.1 Europe - Deals of the Quarter 134
8.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q2 2013 136
8.3.1 Asia-Pacific - Deals of the Quarter 138
8.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q2 2013 139
8.4.1 Rest of the World - Deals of the Quarter 141
9 Pharmaceuticals & Healthcare, Global, Top Advisors 143
9.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Last One Year 143
9.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Last One Year 145
10 Appendix 147
11 Further Information 151
11.1 Methodology 151
11.2 About GlobalData 152
11.3 Disclosure information 153
11.4 Disclaimer 153

List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q2 2012 - Q2 2013 17
Table 2: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), Q2 2013 19
Table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q2 2013 20
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2012 - Q2 2013 27
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, Q2 2013 28
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, , Q2 2012 - Q2 2013 30
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q2 2012 - Q2 2013 32
Table 8: Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q2 2013 32
Table 9: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q2 2013 32
Table 10: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q2 2013 33
Table 11: Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q2 2012-Q2 2013 33
Table 12: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q2 2012 - Q2 2013 35
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2012 - Q2 2013 37
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q2 2013 37
Table 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), Q2 2013 39
Table 16: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q2 2012 - Q2 2013 41
Table 17: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q3 2012 - Q2 2013 43
Table 18: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q3 2012 - Q2 2013 44
Table 19: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2012 - Q2 2013 46
Table 20: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q2 2013 46
Table 21: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q2 2012 - Q2 2013 48
Table 22: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q2 2012 - Q2 2013 50
Table 23: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q2 2012 - Q2 2013 52
Table 24: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q2 2012 - Q2 2013 54
Table 25: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payments and Deal Values (US$ m), Q2 2013 54
Table 26: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q2 2013 55
Table 27: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q2 2013 56
Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q2 2012 - Q2 2013 58
Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q2 2012 - Q2 2013 61
Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q2 2012 - Q2 2013 63
Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q2 2012 - Q2 2013 65
Table 32: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payments and Deal Values (US$ m), Q2 2012 - Q2 2013 67
Table 33: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q2 2013 68
Table 34: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q2 2013 68
Table 35: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q2 2013 69
Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q2 2012 - Q2 2013 71
Table 37: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), Q2 2012 - Q2 2013 73
Table 38: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q2 2012 - Q2 2013 76
Table 39: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Values (US$ m), Q2 2012 - Q2 2013 78
Table 40: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q2 2012 - Q2 2013 80
Table 41: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q2 2012 - Q2 2013 82
Table 42: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q2 2012 - Q2 2013 84
Table 43: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Operating Profit, Q2 2012 - Q2 2013 86
Table 44: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q2 2012 - Q2 2013 88
Table 45: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Book Value Per Share, Q2 2012 - Q2 2013 89
Table 46: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q2 2012 - Q2 2013 91
Table 47: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2012 - Q2 2013 93
Table 48: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2012 - Q2 2013 97
Table 49: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2012 - Q2 2013 100
Table 50: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2012 - Q2 2013 104
Table 51: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2012 - Q2 2013 107
Table 52: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2012 - Q2 2013 111
Table 53: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2012 - Q2 2013 115
Table 54: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2012 - Q2 2013 118
Table 55: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2012 - Q2 2013 121
Table 56: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2012 - Q2 2013 125
Table 57: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2012 - Q2 2013 128
Table 58: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2012 - Q2 2013 133
Table 59: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2012 - Q2 2013 137
Table 60: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2012 - Q2 2013 140
Table 61: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q3 2012 - Q2 2013 144
Table 62: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q3 2012 - Q2 2013 146
Table 63: Pharmaceuticals & Healthcare, Deals’ Key Financials, Global Acquisition Deals, Q2 2012-Q2 2013 147

List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$m), Q2 2012 - Q2 2013 15
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), Q2 2013 18
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), Q2 2013 19
Figure 4: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$m), Q2 2012 - Q2 2013 26
Figure 5: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, Q2 2012 - Q2 2013 29
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q2 2012 - Q2 2013 31
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), , Q2 2012 - Q2 2013 34
Figure 8: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q2 2012 - Q2 2013 36
Figure 9: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), Q2 2013 38
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), Q2 2013 39
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q2 2012 - Q2 2013 40
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q3 2012 - Q2 2013 42
Figure 13: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q2 2012 - Q2 2013 45
Figure 14: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q2 2012 - Q2 2013 47
Figure 15: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q2 2012 - Q2 2013 49
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q2 2012 - Q2 2013 51
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), Q2 2012 - Q2 2013 53
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q2 2012 - Q2 2013 57
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q2 2012 - Q2 2013 59
Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q2 2012 - Q2 2013 60
Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), Q2 2012 - Q2 2013 62
Figure 22:Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q2 2012 - Q2 2013 64
Figure 23:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2012 - Q2 2013 66
Figure 24:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q2 2012 - Q2 2013 70
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), Q2 2012 - Q2 2013 72
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number of Deals, Q2 2012 - Q2 2013 74
Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), Q2 2012 - Q2 2013 75
Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2012 - Q2 2013 77
Figure 29:Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q2 2012 - Q2 2013 79
Figure 30: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q2 2012 - Q2 2013 81
Figure 31: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q2 2012 - Q2 2013 83
Figure 32: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q2 2012 - Q2 2013 85
Figure 33: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q2 2012 - Q2 2013 87
Figure 34: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Book Value Per Share, Q2 2012 - Q2 2013 89
Figure 35:Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q2 2012 - Q2 2013 90
Figure 36: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q2 2012 - Q2 2013 92
Figure 37: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q2 2012 - Q2 2013 96
Figure 38: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (US$ m), Q2 2012 - Q2 2013 99
Figure 39: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q2 2012 - Q2 2013 103
Figure 40: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q2 2012 - Q2 2013 106
Figure 41: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q2 2012 - Q2 2013 110
Figure 42: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2012 - Q2 2013 114
Figure 43: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2012 - Q2 2013 117
Figure 44: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2012 - Q2 2013 120
Figure 45: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2012 - Q2 2013 124
Figure 46: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), Q2 2012 - Q2 2013 127
Figure 47: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), Q2 2012 - Q2 2013 132
Figure 48: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), Q2 2012 - Q2 2013 136
Figure 49: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), Q2 2012 - Q2 2013 139
Figure 50: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q3 2012 - Q2 2013 143
Figure 51: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q3 2012 - Q2 2013 145

Read the full report:

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q2 2013

http://www.reportbuyer.com/banking_finance/capital_markets/partnerships_licensing_investments_ma_deals_trends_pharmaceuticals_q2_2013.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Investment_Banking

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: http://www.reportbuyer.com/

Read the full story at http://www.prweb.com/releases/2013/10/prweb11274865.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved


Related medicine news :

1. Avacade Investments Reveals Promising Green Investment Trends
2. Palo Alto Seals the Deal on Major Solar Electric Investments
3. Fidelity Investments Brings the Happiness of the Holidays to Five Educational First Steps Assisted Centers
4. San Francisco EB-5 Conference explores inbound Chinese investments
5. EB-5 Expert Brian Su Explores Chinese Inbound Investments in Southern California
6. Download Merrill DataSite's Report - M&A Monthly Insider, October 2013
7. Register to Download the Merrill DataSite's White Paper: The Seven Critical M&A Transaction Mistakes and How to Avoid Them
8. Download the Merrill DataSite's Report - Driving Successful Cross-Border M&A Transactions
9. Download the Merrill DataSite Complimentary Roundtable Report: M&A 2013 – Navigating the Regulatory Storm
10. Merrill DataSite Releases New Comments: Cash Reserves and M&A Options
11. Register to Join Merrill DataSite's Webinar: M&A Regulatory and Tax Changes and Their Impact on Deal Structure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... 2016 , ... Be Well Medical Group (Be Well) is pleased ... at 108 South Columbus St, Suite 201, Alexandria, VA. Be Well Medical Group is ... the convenience of their homes, offices or at the practices’ local office. It is ...
(Date:2/11/2016)... ... , ... The book, “Computers Should Just Work!”, provides a basic, non-techie education ... consultant before signing a contract and how to spot an incompetent or dishonest IT ... on e-mail and technology, it’s more important than ever to make sure the company ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... practitioner, is known locally for a series of therapeutic sessions to help Los ... their characters and in their lives. The series, known as “Mindfulness for Actors ...
(Date:2/10/2016)... ... February 10, 2016 , ... MetLoop CEO Jay ... 2.0 version at the International Roofing Expo in Orlando, Florida on February 17-19. ... most advanced weather technology in the hands of consumers, roofing contractors, manufacturers and ...
(Date:2/10/2016)... ... February 10, 2016 , ... The Wickman Agency in ... assist the local community. Pledging to select a new beneficiary every 60 days, ... area. Their goal is to bring community awareness to important local causes by ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... -- Fotona, based in the U.S. and Europe ... Lightwalker dental laser at the upcoming 151 st Midwinter ... in booth #4815. The ST PRO is a full featured ... features of the award winning, industry leading Lightwalker ATS. At an ... be very attractive to many dentists hesitating to incorporate lasers ...
(Date:2/10/2016)... Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ), today ... and full year ended December 31, 2015. ... transformational year for Vanda with the continued growth of ... of HETLIOZ for Non-24," said Mihael H. Polymeropoulos, M.D., ... our U.S. product portfolio builds on this success and ...
(Date:2/10/2016)... 2016 A new report from business intelligence provider GBI ... the Alzheimer,s disease market will more than double from just under $5 billion ... Growth Rate (CAGR) of 11%. Canada , ... Spain , the UK, and Japan , ... --> Canada , France , ...
Breaking Medicine Technology: